{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:15:10Z","timestamp":1789784110987,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T00:00:00Z","timestamp":1559865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T00:00:00Z","timestamp":1559865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13023-019-1085-6","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T15:02:45Z","timestamp":1559919765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4686-0412","authenticated-orcid":false,"given":"M. Judith","family":"Peterschmitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selena","family":"Freisens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa H.","family":"Underhill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith C.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan J. M.","family":"Gaemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,7]]},"reference":[{"key":"1085_CR1","unstructured":"Grabowski GA, Petsko GA, Kolodny EH. Gaucher disease. 2013 [cited December 6, 2018]. In: OMMBID: The Online Metabolic and Molecular Bases of Inherited Disease [Internet]. New York, NY: McGraw-Hill, [cited December 6, 2018]; [Available at: \n                    http:\/\/ommbid.mhmedical.com\/content.aspx?bookid=971%A7ionid=62643884\n                    \n                  ]."},{"issue":"2","key":"1085_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/path.3021","volume":"226","author":"TM Cox","year":"2012","unstructured":"Cox TM, Cachon-Gonzalez MB. The cellular pathology of lysosomal diseases. J Pathol. 2012;226(2):241\u201354.","journal-title":"J Pathol"},{"issue":"Suppl 1","key":"1085_CR3","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1002\/ajh.24055","volume":"90","author":"PK Mistry","year":"2015","unstructured":"Mistry PK, Belmatoug N, vom Dahl S, Giugliani R. Understanding the natural history of Gaucher disease. Am J Hematol. 2015;90(Suppl 1):S6\u201311.","journal-title":"Am J Hematol"},{"key":"1085_CR4","unstructured":"CERDELGA\u2122 (eliglustat) [package insert]. Genzyme Corporation, a Sanofi Company, Waterford, Ireland. 2018. \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/205494s003lbl.pdf\n                    \n                  . Accessed 4 Dec 2018."},{"key":"1085_CR5","unstructured":"CERDELGA\u2122 84 mg capsules. Summary of Product Characteristics. Genzyme Therapeutics, Oxfordshire, United Kingdom. 2018. \n                    http:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cerdelga-epar-product-information_en.pdf\n                    \n                  . Accessed 4 Dec 2018."},{"issue":"5","key":"1085_CR6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/clpt.2013.2","volume":"93","author":"JK Hicks","year":"2013","unstructured":"Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013;93(5):402\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"1085_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.bcmd.2017.01.006","volume":"68","author":"MJ Peterschmitt","year":"2018","unstructured":"Peterschmitt MJ, Cox GF, Ibrahim J, MacDougall J, Underhill LH, Patel P, et al. A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: evaluation of frequency, timing, and duration. Blood Cells Mol Dis. 2018;68:185\u201391.","journal-title":"Blood Cells Mol Dis"},{"issue":"6","key":"1085_CR8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina E, Watman N, Arreguin EA, Banikazemi M, Dragosky M, Iastrebner M, et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 2010;116(6):893\u20139.","journal-title":"Blood."},{"issue":"7","key":"1085_CR9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/jama.2015.459","volume":"313","author":"PK Mistry","year":"2015","unstructured":"Mistry PK, Lukina E, Ben Turkia H, Amato D, Baris H, Dasouki M, et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA. 2015;313(7):695\u2013706.","journal-title":"JAMA."},{"issue":"9985","key":"1085_CR10","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","volume":"385","author":"TM Cox","year":"2015","unstructured":"Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, et al. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet. 2015;385(9985):2355\u201362.","journal-title":"Lancet."},{"issue":"3","key":"1085_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ymgme.2017.12.001","volume":"123","author":"J Charrow","year":"2018","unstructured":"Charrow J, Fraga C, Gu X, Ida H, Longo N, Lukina E, et al. Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: the phase 3, randomized, double-blind EDGE trial. Mol Genet Metab. 2018;123(3):347\u201356.","journal-title":"Mol Genet Metab"},{"issue":"20","key":"1085_CR12","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina E, Watman N, Arreguin EA, Dragosky M, Iastrebner M, Rosenbaum H, et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood. 2010;116(20):4095\u20138.","journal-title":"Blood."},{"issue":"4","key":"1085_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.bcmd.2014.04.002","volume":"53","author":"E Lukina","year":"2014","unstructured":"Lukina E, Watman N, Dragosky M, Pastores GM, Arreguin EA, Rosenbaum H, et al. Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4 years of treatment. Blood Cells Mol Dis. 2014;53(4):274\u20136.","journal-title":"Blood Cells Mol Dis"},{"key":"1085_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/ajh.25300","volume":"94","author":"E Lukina","year":"2019","unstructured":"Lukina E, Watman N, Dragosky M, Lau H, Avila Arreguin E, Rosenbaum H, et al. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: final results from the phase 2 trial. Am J Hematol. 2019;94:29\u201338.","journal-title":"Am J Hematol"},{"issue":"11","key":"1085_CR15","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/ajh.24877","volume":"92","author":"PK Mistry","year":"2017","unstructured":"Mistry PK, Lukina E, Ben Turkia H, Shankar SP, Baris H, Ghosn M, et al. Outcomes after 18 months of eliglustat therapy in treatment-naive adults with Gaucher disease type 1: the phase 3 ENGAGE trial. Am J Hematol. 2017;92(11):1170\u20136.","journal-title":"Am J Hematol"},{"issue":"17","key":"1085_CR16","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-12-758409","volume":"129","author":"TM Cox","year":"2017","unstructured":"Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, et al. Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy. Blood. 2017;129(17):2375\u201383.","journal-title":"Blood."},{"issue":"2","key":"1085_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","volume":"90","author":"K Starzyk","year":"2007","unstructured":"Starzyk K, Richards S, Yee J, Smith SE, Kingma W. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab. 2007;90(2):157\u201363.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"1085_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","volume":"36","author":"NJ Weinreb","year":"2013","unstructured":"Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, et al. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis. 2013;36(3):543\u201353.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"1085_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ymgme.2015.09.002","volume":"117","author":"M Balwani","year":"2016","unstructured":"Balwani M, Burrow TA, Charrow J, Goker-Alpan O, Kaplan P, Kishnani PS, et al. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. Mol Genet Metab. 2016;117(2):95\u2013103.","journal-title":"Mol Genet Metab"},{"key":"1085_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejim.2016.07.011","volume":"37","author":"N Belmatoug","year":"2017","unstructured":"Belmatoug N, Di Rocco M, Fraga C, Giraldo P, Hughes D, Lukina E, et al. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. Eur J Intern Med. 2017;37:25\u201332.","journal-title":"Eur J Intern Med"},{"key":"1085_CR21","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). ICH Harmonised Tripartite Guideline Clinical Safety Data Management: Definitions and Standards for Expedited Reporting E2A. 1994. \n                    https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E2A\/Step4\/E2A_Guideline.pdf\n                    \n                  . Accessed 11 Dec 2018."},{"issue":"2","key":"1085_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/jnnp.2006.111518","volume":"79","author":"JL Capablo","year":"2008","unstructured":"Capablo JL, Saenz de Cabezon A, Fraile J, Alfonso P, Pocovi M, Giraldo P. Neurological evaluation of patients with Gaucher disease diagnosed as type 1. J Neurol Neurosurg Psychiatry. 2008;79(2):219\u201322.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"1085_CR23","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1093\/brain\/awq198","volume":"133","author":"M Biegstraaten","year":"2010","unstructured":"Biegstraaten M, Mengel E, Marodi L, Petakov M, Niederau C, Giraldo P, et al. Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. Brain. 2010;133(10):2909\u201319.","journal-title":"Brain."},{"key":"1085_CR24","unstructured":"Zavesca (miglustat) Summary of Product Characteristics: Actelion Pharmaceuticals UK Ltd; 2013. \n                    https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zavesca-epar-product-information_en.pdf\n                    \n                  . Accessed 23 Sept 2016."},{"key":"1085_CR25","unstructured":"Zavesca (miglustat) US Prescribing Information. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2014 July 24, 2014. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021348s010lbl.pdf\n                    \n                  . Accessed 22 Sept 2016."},{"issue":"5","key":"1085_CR26","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10545-007-0621-z","volume":"30","author":"P Grigorescu Sido","year":"2007","unstructured":"Grigorescu Sido P, Drugan C, Cret V, Al-Kzouz C, Denes C, Coldea C, et al. Outcome of enzyme replacement therapy in patients with Gaucher disease type I. the Romanian experience. J Inherit Metab Dis. 2007;30(5):783\u20139.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"1085_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0002-9343(97)00134-4","volume":"103","author":"CE Hollak","year":"1997","unstructured":"Hollak CE, Corssmit EP, Aerts JM, Endert E, Sauerwein HP, Romijn JA, et al. Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease. Am J Med. 1997;103(3):185\u201391.","journal-title":"Am J Med"},{"issue":"3","key":"1085_CR28","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.bcmd.2007.09.002","volume":"40","author":"M Langeveld","year":"2008","unstructured":"Langeveld M, de Fost M, Aerts JM, Sauerwein HP, Hollak CE. Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy. Blood Cells Mol Dis. 2008;40(3):428\u201332.","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"1085_CR29","first-page":"S116","volume":"123","author":"MJ Peterschmitt","year":"2018","unstructured":"Peterschmitt MJ, Hou AW, Underhill LH, Wu Y, Gaemers SJM. Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1. Molec Genet Metab. 2018;123(2):S116.","journal-title":"Molec Genet Metab"},{"key":"1085_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.bcmd.2018.04.001","volume":"71","author":"PK Mistry","year":"2018","unstructured":"Mistry PK, Balwani M, Baris HN, Turkia HB, Burrow TA, Charrow J, et al. Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. Blood Cells Mol Dis. 2018;71:71\u20134.","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"1085_CR31","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1021\/jm901281m","volume":"53","author":"T Wennekes","year":"2010","unstructured":"Wennekes T, Meijer AJ, Groen AK, Boot RG, Groener JE, van Eijk M, et al. Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation. J Med Chem. 2010;53(2):689\u201398.","journal-title":"J Med Chem"},{"issue":"5","key":"1085_CR32","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ana.21491","volume":"64","author":"R Schiffmann","year":"2008","unstructured":"Schiffmann R, Fitzgibbon EJ, Harris C, DeVile C, Davies EH, Abel L, et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Ann Neurol. 2008;64(5):514\u201322.","journal-title":"Ann Neurol"},{"issue":"8","key":"1085_CR33","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1358\/dof.2010.035.08.1505566","volume":"35","author":"JA Shayman","year":"2010","unstructured":"Shayman JA. Eliglustat tartrate: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease. Drugs Future. 2010;35(8):613\u201320.","journal-title":"Drugs Future"},{"key":"1085_CR34","unstructured":"CEREZYME\u2122 (imiglucerase for injection) package insert. Waterford, Ireland: Genzyme Corporation, a Sanofi Company; 2018. \n                    http:\/\/products.sanofi.us\/cerezyme\/cerezyme.pdf\n                    \n                  . Accessed 27 Nov 2018."},{"issue":"1","key":"1085_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bcmd.2010.10.008","volume":"46","author":"D Doneda","year":"2011","unstructured":"Doneda D, Lopes AL, Oliveira AR, Netto CB, Moulin CC, Schwartz IV. Gaucher disease type I: assessment of basal metabolic rate in patients from southern Brazil. Blood Cells Mol Dis. 2011;46(1):42\u20136.","journal-title":"Blood Cells Mol Dis"},{"key":"1085_CR36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bcmd.2016.10.012","volume":"68","author":"F Nascimbeni","year":"2018","unstructured":"Nascimbeni F, Dalla Salda A, Carubbi F. Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease. Blood Cells Mol Dis. 2018;68:74\u201380.","journal-title":"Blood Cells Mol Dis"},{"key":"1085_CR37","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/j.ymgme.2016.11.155","volume":"120","author":"AW Hou","year":"2016","unstructured":"Hou AW, Patel P, Peterschmitt MJ, Ibrahim J, Gaemers SJM. Two-year postmarketing safety experience with oral eliglustat in adults with type 1 Gaucher disease. Molec Genet Metab. 2016;120:S67.","journal-title":"Molec Genet Metab."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1085-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1085-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1085-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T23:11:15Z","timestamp":1591398675000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1085-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1085"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1085-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,7]]},"assertion":[{"value":"22 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocols for all four studies were approved by the institutional review boards or independent ethics committees of participating institutions (See list in Additional file ).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors are currently employees of Sanofi Genzyme.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"128"}}